Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
LEO Pharma has recently completed the first phase of its strategic transformation process – including the development of a new capital and governance structure. During her more than two years as President and CEO, Catherine Mazzacco has successfully led this effort and developed the company’s sales and marketing capabilities while at the same time building a strong executive leadership team.
The next phase of LEO Pharma’s transformation is focused on preparing the company for an IPO within a four- to five-year time horizon. This requires a focus on operational efficiency, shareholder and capital markets engagement, and driving the internal strategic transformation of the organization.
The Board of Directors and Catherine Mazzacco have together concluded that this would be the right time for LEO Pharma to recruit a new CEO. Catherine Mazzacco is stepping down from her role and leaving the company on November 30, 2021.
Catherine Mazzacco says:
“It has been a privilege to be the CEO of LEO Pharma and I have a tremendous affection for LEO Pharma employees and their high level of engagement for the company. I am proud of the accomplishments we have achieved together in setting an ambitious strategy for the company, completing a comprehensive efficiency improvement program, establishing a new capital structure and advancing the launch of a major new therapy.”
The Chairman of the Board, Jesper Brandgaard, says:
“On behalf of the Board, I would like to express our sincere thanks to Catherine Mazzacco for her commendable efforts in leading the transformation of LEO Pharma towards a leadership position in the innovative space of medical dermatology. Catherine Mazzacco has been instrumental in driving the company’s ambitious growth strategy towards 2030.”
The Board of Directors has initiated a search process for the next CEO. Until a new permanent CEO is in place, the current LEO Pharma CFO, Anders Kronborg, will step in as acting CEO, and the Chairman of the Board, Jesper Brandgaard, will act as Executive Chair.
Contacts
Karen Frost
+45 3166 1567
KASFR@leo-pharma.com
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million.
For more information, please visit www.LEO-Pharma.com.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Presents Data from the Largest-Ever Multinational Real-World Studies of Chronic Hand Eczema (CHE) in Adults at the ESCD 2024 Congress5.9.2024 09:00:00 CEST | Pressemeddelelse
· The CHECK (patient-reported) and RWEAL (physician-reported) studies form the largest multinational CHE surveys conducted in the adult population. (1-5) · Findings show that CHE is common in the general population, with around 5.6% of study participants self-reporting the condition in the last 12 months. (1-5) · Among people self-reporting CHE, one in five (21.5%) attribute the condition to their occupation, and one in ten (12.2%) of those reporting CHE in relation to occupation or daily activities have changed work assignments or reduced their working hours.(2)
LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year26.8.2024 14:00:00 CEST | Pressemeddelelse
Six-month interim report (H1) 2024 (Unaudited) - NOT FOR UK USE / NOT INTENDED FOR UK MEDIA
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis21.8.2024 15:00:00 CEST | Pressemeddelelse
Results from the randomized, double-blind period of the phase 3 clinical trial with TMB-001 – the ASCEND trial – show that the primary and key secondary endpoints were not met. The trial investigated TMB-001 in patients 6 years or older with moderate to severe congenital ichthyosis. The majority of adverse events observed were non-serious localized skin reactions of mild or moderate severity. The trial results do not support submission of a New Drug Application to the US FDA. NOT FOR UK USE – NOT INTENDED FOR UK MEDIA
Change in the Board of Directors of LEO Pharma31.7.2024 10:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, July 31, 2024 – Today, LEO Pharma A/S announced that non-executive director Jan van de Winkel has decided to step down from the Board of Directors of LEO Pharma effective August 1, 2024 due to increasing time commitments from his primary executive position as Chief Executive Officer of Genmab A/S. Jan van de Winkel joined the Board of Directors in March, 2017. Chair of the Board of Directors, Jesper Brandgaard said: “I would like to express my sincere gratitude to Jan for his loyal service and valuable contributions to LEO Pharma as a non-executive board member throughout times of great change and transformation. I am pleased that Jan has offered to provide his advice to the Chairmanship in the process leading up to the potential public listing of LEO Pharma.”
LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE)26.7.2024 08:00:00 CEST | Pressemeddelelse
The positive opinion marks the latest step towards marketing authorization in the European Union (EU), with a final decision from the European Commission (EC) now pending. If approved, delgocitinib cream will be the first topical treatment specifically indicated for adults with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate. The positive opinion is based on results from the DELTA phase 3 program, which includes the randomized, vehicle-controlled DELTA 1 and DELTA 2 clinical trials, (1,2,3) and the DELTA 3 open-label extension trial.(4)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom